Nordhealth AS (NORDH.OL) Stock Analysis & AI Equity Report

Medical - Healthcare Information Services NOK Explore free reports

Nordhealth AS (NORDH.OL) overview

Nordhealth AS (NORDH.OL) stock analysis and AI equity research. For the latest completed financial year, 2025, Nordhealth AS reported revenue of EUR 50.3m and operating profit of EUR -12.6m; the year-end share price was 37.00 NOK and market capitalisation was NOK 2,967m. Nordhealth AS is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Nordhealth AS's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueEUR 61.5mFY 2025
Share price37.00 NOKFY 2025 year end
RevenueEUR 50.3mFY 2025
Operating profitEUR -12.6mFY 2025
Net earningsEUR -12.5mFY 2025
Market capitalisationNOK 2,967mFY 2025 year end

Figures updated on 2026-05-11. Data will be refreshed during report generation.

About Nordhealth AS

Nordhealth is a healthcare software company that develops and acquires cloud-based practice management products for veterinary and therapy providers. Its core offerings include Provet and Therapy Unified Platform, which support scheduling, booking, invoicing, patient communication, and workflow management. The company also provides related APIs and integrations for clinics and hospitals across multiple markets.

Generate the Nordhealth AS report

Nordhealth AS is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Nordhealth AS and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.